Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 26 08 2018
revised: 30 01 2019
accepted: 31 01 2019
pubmed: 5 3 2019
medline: 13 7 2019
entrez: 5 3 2019
Statut: ppublish

Résumé

Transcriptional dysregulation drives cancer formation but the underlying mechanisms are still poorly understood. Renal cell carcinoma (RCC) is the most common malignant kidney tumor which canonically activates the hypoxia-inducible transcription factor (HIF) pathway. Despite intensive study, novel therapeutic strategies to target RCC have been difficult to develop. Since the RCC epigenome is relatively understudied, we sought to elucidate key mechanisms underpinning the tumor phenotype and its clinical behavior. We performed genome-wide chromatin accessibility (DNase-seq) and transcriptome profiling (RNA-seq) on paired tumor/normal samples from 3 patients undergoing nephrectomy for removal of RCC. We incorporated publicly available data on HIF binding (ChIP-seq) in a RCC cell line. We performed integrated analyses of these high-resolution, genome-scale datasets together with larger transcriptomic data available through The Cancer Genome Atlas (TCGA). Though HIF transcription factors play a cardinal role in RCC oncogenesis, we found that numerous transcription factors with a RCC-selective expression pattern also demonstrated evidence of HIF binding near their gene body. Examination of chromatin accessibility profiles revealed that some of these transcription factors influenced the tumor's regulatory landscape, notably the stem cell transcription factor POU5F1 (OCT4). Elevated POU5F1 transcript levels were correlated with advanced tumor stage and poorer overall survival in RCC patients. Unexpectedly, we discovered a HIF-pathway-responsive promoter embedded within a endogenous retroviral long terminal repeat (LTR) element at the transcriptional start site of the PSOR1C3 long non-coding RNA gene upstream of POU5F1. RNA transcripts are induced from this promoter and read through PSOR1C3 into POU5F1 producing a novel POU5F1 transcript isoform. Rather than being unique to the POU5F1 locus, we found that HIF binds to several other transcriptionally active LTR elements genome-wide correlating with broad gene expression changes in RCC. Integrated transcriptomic and epigenomic analysis of matched tumor and normal tissues from even a small number of primary patient samples revealed remarkably convergent shared regulatory landscapes. Several transcription factors appear to act downstream of HIF including the potent stem cell transcription factor POU5F1. Dysregulated expression of POU5F1 is part of a larger pattern of gene expression changes in RCC that may be induced by HIF-dependent reactivation of dormant promoters embedded within endogenous retroviral LTRs.

Sections du résumé

BACKGROUND BACKGROUND
Transcriptional dysregulation drives cancer formation but the underlying mechanisms are still poorly understood. Renal cell carcinoma (RCC) is the most common malignant kidney tumor which canonically activates the hypoxia-inducible transcription factor (HIF) pathway. Despite intensive study, novel therapeutic strategies to target RCC have been difficult to develop. Since the RCC epigenome is relatively understudied, we sought to elucidate key mechanisms underpinning the tumor phenotype and its clinical behavior.
METHODS METHODS
We performed genome-wide chromatin accessibility (DNase-seq) and transcriptome profiling (RNA-seq) on paired tumor/normal samples from 3 patients undergoing nephrectomy for removal of RCC. We incorporated publicly available data on HIF binding (ChIP-seq) in a RCC cell line. We performed integrated analyses of these high-resolution, genome-scale datasets together with larger transcriptomic data available through The Cancer Genome Atlas (TCGA).
FINDINGS RESULTS
Though HIF transcription factors play a cardinal role in RCC oncogenesis, we found that numerous transcription factors with a RCC-selective expression pattern also demonstrated evidence of HIF binding near their gene body. Examination of chromatin accessibility profiles revealed that some of these transcription factors influenced the tumor's regulatory landscape, notably the stem cell transcription factor POU5F1 (OCT4). Elevated POU5F1 transcript levels were correlated with advanced tumor stage and poorer overall survival in RCC patients. Unexpectedly, we discovered a HIF-pathway-responsive promoter embedded within a endogenous retroviral long terminal repeat (LTR) element at the transcriptional start site of the PSOR1C3 long non-coding RNA gene upstream of POU5F1. RNA transcripts are induced from this promoter and read through PSOR1C3 into POU5F1 producing a novel POU5F1 transcript isoform. Rather than being unique to the POU5F1 locus, we found that HIF binds to several other transcriptionally active LTR elements genome-wide correlating with broad gene expression changes in RCC.
INTERPRETATION CONCLUSIONS
Integrated transcriptomic and epigenomic analysis of matched tumor and normal tissues from even a small number of primary patient samples revealed remarkably convergent shared regulatory landscapes. Several transcription factors appear to act downstream of HIF including the potent stem cell transcription factor POU5F1. Dysregulated expression of POU5F1 is part of a larger pattern of gene expression changes in RCC that may be induced by HIF-dependent reactivation of dormant promoters embedded within endogenous retroviral LTRs.

Identifiants

pubmed: 30827930
pii: S2352-3964(19)30069-6
doi: 10.1016/j.ebiom.2019.01.063
pmc: PMC6441874
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
ENPP3 protein, human 0
Hypoxia-Inducible Factor 1 0
Octamer Transcription Factor-3 0
POU5F1 protein, human 0
PSORS1C3 lncRNA, human 0
Proteins 0
RNA, Long Noncoding 0
endothelial PAS domain-containing protein 1 1B37H0967P
Cytochrome Reductases EC 1.6.2.-
GFER protein, human EC 1.8.-
Oxidoreductases Acting on Sulfur Group Donors EC 1.8.-
UBE2D2 protein, human EC 2.3.2.23
Ubiquitin-Conjugating Enzymes EC 2.3.2.23
Phosphoric Diester Hydrolases EC 3.1.4.-
Pyrophosphatases EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-442

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
Anticancer Res. 1999 May-Jun;19(3A):2105-10
pubmed: 10470156
Hum Pathol. 2001 Mar;32(3):282-7
pubmed: 11274636
Mamm Genome. 2001 Apr;12(4):309-17
pubmed: 11309664
Comput Chem. 2001 Dec;26(1):51-6
pubmed: 11765852
J Urol. 2002 Aug;168(2):762-5
pubmed: 12131365
Clin Cancer Res. 2003 Mar;9(3):1021-7
pubmed: 12631601
Oncol Res. 1992;4(11-12):467-72
pubmed: 1299377
Nucleic Acids Res. 1992 Sep 11;20(17):4613-20
pubmed: 1408763
Br J Cancer. 2004 Mar 22;90(6):1235-43
pubmed: 15026807
J Biol Chem. 2004 Oct 1;279(40):42169-81
pubmed: 15280377
Hum Mol Genet. 2005 Mar 1;14(5):603-14
pubmed: 15649945
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4783-8
pubmed: 15772165
J Urol. 2005 Jun;173(6):2150-3
pubmed: 15879877
FASEB J. 2005 Aug;19(10):1296-8
pubmed: 15919761
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10
pubmed: 16381825
Mol Cell Biol. 2007 Mar;27(6):2092-102
pubmed: 17220275
Genome Biol. 2007;8(2):R24
pubmed: 17324271
Nucleic Acids Res. 2008 Jan;36(Database issue):D102-6
pubmed: 18006571
Cell. 2008 Jan 25;132(2):311-22
pubmed: 18243105
Cell Stem Cell. 2007 Oct 11;1(4):364-6
pubmed: 18371374
FASEB J. 2008 Oct;22(10):3696-705
pubmed: 18614581
Genome Res. 2008 Nov;18(11):1752-62
pubmed: 18682548
Cancer Biol Ther. 2008 Nov;7(11):1787-92
pubmed: 18787400
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Stem Cells Dev. 2008 Oct;17(5):869-81
pubmed: 18811242
BMC Bioinformatics. 2009 Feb 03;10:48
pubmed: 19192299
Cancer Res. 2009 Mar 15;69(6):2506-13
pubmed: 19244102
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Clin Cancer Res. 2009 May 15;15(10):3297-304
pubmed: 19401348
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Reproduction. 2010 Jan;139(1):85-97
pubmed: 19755485
Exp Cell Res. 2010 Feb 1;316(3):466-76
pubmed: 19786016
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Nat Med. 2010 May;16(5):571-9, 1p following 579
pubmed: 20436485
Br J Cancer. 2010 May 25;102(11):1592-9
pubmed: 20461084
Cancer Cell. 2010 Nov 16;18(5):472-84
pubmed: 21075312
Cancer Res. 2011 Feb 1;71(3):716-24
pubmed: 21266363
Blood. 2011 Apr 21;117(16):4304-14
pubmed: 21304103
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Am J Surg Pathol. 2011 Jun;35(6):816-26
pubmed: 21552115
BMC Cancer. 2011 Jun 13;11:244
pubmed: 21668985
Cancer Res. 2011 Jul 1;71(13):4640-52
pubmed: 21712410
Carcinogenesis. 2011 Nov;32(11):1713-23
pubmed: 21880579
Cancer Res. 2011 Nov 1;71(21):6601-10
pubmed: 21920898
Am J Surg Pathol. 2011 Oct;35(10):1473-83
pubmed: 21934480
Cancer Cell. 2011 Oct 18;20(4):418-20
pubmed: 22014567
J Clin Pathol. 2012 Mar;65(3):254-6
pubmed: 22135028
PLoS One. 2012;7(1):e30377
pubmed: 22276185
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Bioinformatics. 2012 Jul 15;28(14):1919-20
pubmed: 22576172
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
Neoplasma. 2012;59(6):599-605
pubmed: 22862160
PLoS One. 2012;7(8):e40724
pubmed: 22899991
Nature. 2012 Sep 6;489(7414):75-82
pubmed: 22955617
J Transl Med. 2012 Sep 24;10:200
pubmed: 23006512
Urology. 2012 Dec;80(6):1298-302.e1
pubmed: 23206776
Nat Biotechnol. 2013 Jan;31(1):46-53
pubmed: 23222703
Curr Cancer Drug Targets. 2013 Feb;13(2):126-42
pubmed: 23259857
Med Oncol. 2013 Mar;30(1):346
pubmed: 23263830
Cell. 2013 Jan 17;152(1-2):327-39
pubmed: 23332764
Cancer Res. 2013 Apr 1;73(7):2044-51
pubmed: 23365135
Cell Signal. 2013 May;25(5):1212-21
pubmed: 23416459
Nat Protoc. 2013 Apr;8(4):737-48
pubmed: 23493070
PLoS Genet. 2013 May;9(5):e1003504
pubmed: 23675311
Stem Cells. 2013 Sep;31(9):1737-48
pubmed: 23765801
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cell. 2013 Aug 15;154(4):888-903
pubmed: 23953118
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Nat Genet. 2014 Mar;46(3):225-233
pubmed: 24487277
Cell Stem Cell. 2014 May 1;14(5):592-605
pubmed: 24656769
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3534-43
pubmed: 25114248
Nature. 2014 Nov 20;515(7527):355-64
pubmed: 25409824
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Nature. 2015 Feb 19;518(7539):360-364
pubmed: 25693567
PLoS One. 2015 Aug 11;10(8):e0134645
pubmed: 26262842
Oncogene. 2016 May 12;35(19):2542-6
pubmed: 26279299
Nature. 2015 Oct 15;526(7573):453-7
pubmed: 26444240
Elife. 2015 Nov 17;4:null
pubmed: 26575290
Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62
pubmed: 26576779
Clin Cancer Res. 2016 Apr 15;22(8):1989-99
pubmed: 26589436
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Sci Rep. 2016 Feb 25;6:21968
pubmed: 26912277
Cell Rep. 2016 Mar 15;14(10):2476-89
pubmed: 26947078
Nat Commun. 2016 Jul 07;7:12098
pubmed: 27384883
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Epigenetics Chromatin. 2016 Nov 9;9:50
pubmed: 27833659
Mob DNA. 2016 Dec 1;7:24
pubmed: 27980689
Eur J Cell Biol. 2017 Jun;96(4):347-355
pubmed: 28476334
Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
Cancer Cell. 2017 Jul 10;32(1):27-41.e4
pubmed: 28625481
PLoS Genet. 2017 Jul 17;13(7):e1006872
pubmed: 28715484
Nature. 1988 Mar 17;332(6161):268-9
pubmed: 2894613
Proteomics Clin Appl. 2017 Dec;11(11-12):null
pubmed: 28975715
Int J Oncol. 2018 Jun;52(6):2069-2078
pubmed: 29620155
Cell. 2018 Apr 5;173(2):338-354.e15
pubmed: 29625051
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
Science. 2018 Oct 26;362(6413):
pubmed: 30361341
J Am Soc Nephrol. 2019 Feb 13;:
pubmed: 30760496
Cancer Res. 1995 Sep 15;55(18):4092-8
pubmed: 7664285
Cancer Res. 1995 Feb 1;55(3):658-62
pubmed: 7834636
J Natl Cancer Inst. 1994 Oct 5;86(19):1470-5
pubmed: 8089867
Cancer Res. 1993 Jul 1;53(13):3092-7
pubmed: 8319216
Cancer Lett. 1996 Mar 29;101(2):205-10
pubmed: 8620471
J Mol Biol. 1997 Apr 25;268(1):78-94
pubmed: 9149143

Auteurs

Kyle T Siebenthall (KT)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Chris P Miller (CP)

Department of Pathology, University of Washington, Seattle, WA 98195, United States.

Jeff D Vierstra (JD)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Julie Mathieu (J)

Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98109, United States; Department of Comparative Medicine, University of Washington, Seattle, WA 98195, United States.

Maria Tretiakova (M)

Department of Pathology, University of Washington, Seattle, WA 98195, United States.

Alex Reynolds (A)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Richard Sandstrom (R)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Eric Rynes (E)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Eric Haugen (E)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Audra Johnson (A)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Jemma Nelson (J)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Daniel Bates (D)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Morgan Diegel (M)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Douglass Dunn (D)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Mark Frerker (M)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Michael Buckley (M)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Rajinder Kaul (R)

Altius Institute for Biomedical Sciences, Seattle, WA 98121, United States.

Ying Zheng (Y)

Department of Bioengineering, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States.

Jonathan Himmelfarb (J)

Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States.

Hannele Ruohola-Baker (H)

Department of Biochemistry, University of Washington, Seattle, WA 98195, United States; Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98109, United States.

Shreeram Akilesh (S)

Department of Pathology, University of Washington, Seattle, WA 98195, United States; Kidney Research Institute, Seattle, WA 98104, United States. Electronic address: shreeram@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH